ArticleCancers2019

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy.

Aron Kristof Ghimessy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.